2018年起于北京大学肿瘤医院从事胃肠肿瘤临床工作及相关基础研究。具有扎实的理论知识和一定的临床技能；研究方向是胃肠肿瘤的早诊、分子分型及个体化治疗相关研究。

发表论文

XIE, M., DART, D. A., GUO, T., XING, X. F., CHENG, X. J., DU, H., JIANG, W. G., WEN, X. Z. & JI, J. F. 2018. MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer. Gastric Cancer, 21, 41-54.

XIE, M., DART, D. A., OWEN, S., WEN, X., JI, J. & JIANG, W. 2016. Insights into roles of the miR-1, -133 and -206 family in gastric cancer (Review). Oncol Rep, 36, 1191-8.

XIE, M., HARGEST, R, JIANG, W., Meng Xie, JI, J., DART, D. A. 2018. Relationship of miR-140-5p expression and p53 function and contribution to prognosis prediction and treatment decision of patients with gastric cancer (Abstract). Journal of Clinical Oncology, 36, no. 15_suppl, e24185

XING, X., GUO, J., WEN, X., DING, G., LI, B., DONG, B., FENG, Q., LI, S., ZHANG, J., CHENG, X., GUO, T., DU, H., HU, Y., WANG, X., LI, L., LI, Q., XIE, M., LI, L., GAO, X., SHAN, F., LI, Z., YING, X., ZHOU, T., WANG, J. & JI, J. 2018. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology, 7, e1356144.

GUO, T., WEN, X. Z., LI, Z. Y., HAN, H. B., ZHANG, C. G., BAI, Y. H., XING, X. F., CHENG, X. J., DU, H., HU, Y., WANG, X. H., JIA, Y. N., NIE, M. L., XIE, M., LI, Q. D. & JI, J. F. 2019. ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7. Cell Death Dis, 10, 33.

JIANG, W., MARTIN, T. A., OWEN, S., YE. L., SANDERS, A., J., CUI Y., X., XIE, M., JIA, S., JIA, Y., RUGE F., AVOGADRI-CONNORS, F., LALANI A., BRYCE, R. JI J. Investigating the activity of neratinib in human gastric cancer and gastric cancer cells, implications on clinical outcome and chemotherapy resistance (Abstract 879). 2018. Cancer Research 78 (13 Supplement):879-879